Revance Therapeutics reported $82K in Ordinary Share Capital for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
Aerie Pharmaceuticals AERI:US USD 49K 1000
ALKERMES ALKS:US USD 1.69M 1000
Bristol Myers Squibb BMY:US USD 292M 0
Cara Therapeutics CARA:US USD 53K 0
Coherus Biosciences CHRS:US USD 7K 0
Eli Lilly And LLY:US USD 594.1M 0
Endo International Ordinary Shares ENDP:US USD 63K 3K
Horizon Pharma HZNP:US USD 23K 0
JAZZ PHA JAZZ:US USD 61K 0
Neurocrine Biosciences NBIX:US USD 100K 0
Pacira Pharmaceuticals PCRX:US USD 46K 0
Procter & Gamble PG:US USD 4.01B 0
Revance Therapeutics RVNC:US USD 82K 9K
Supernus Pharmaceuticals SUPN:US USD 54K 1000
Teva Pharmaceutical Industries TEVA:US USD 57M 0